RETRACTED: A long-term effect of epalrestat on motor conduction velocity of diabetic patients: ARI-Diabetes Complications Trial (ADCT)

This article has been retracted at the request of the Editor-in-Chief and Author. Please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy).Reason: The decision has been made to retract this particular published article because it duplicates material published previously in the journal Diabetes Care [1]: namely Table 2 and Figure 1A of the original article were reproduced without permission as Table 2 and Figure 2 in this article. Corresponding author Dr Matsuoka, who was a co-author on the original paper, also failed to seek approval of co-authors named in the duplicate submission. Dr Matsuoka brought this issue to the attention of the Publishers; he assumes full responsibility and apologises for his actions.Reference1. N. Hotta, Y. Akanuma, R. Kawamori, K. Matsuoka, Y. Oka, M. Shichiri, et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: The 3-year, multicenter, comparative aldose reductase inhibitor-diabetes complications trial. Diabetes Care 29 (7) 1538–1544.Nigishi Hotta M.D., Ph.D. Honorary Editor-in-Chief, Diabetes Research and Clinical Practice, Professor Emeritus Nagoya University, Director General, Japan Labour Health and Welfare Organization Chubu Rosai Hospital, 1-10-6 Komei, Minato-ku, Nagoya 455-8530, Japan.Andrew Miller, Ph.D. Senior Publishing Editor, Elsevier, Health Sciences, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, UK.